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Combination of stem cell-based approaches with
gene-editing technologies represents an attractive
strategy for studying human disease and developing
therapies. However, gene-editing methodologies
described todate for humancells suffer fromtechnical
limitations including limited target gene size, low tar-
geting efficiency at transcriptionally inactive loci, and
off-target genetic effects that could hamper broad
clinical application. To address these limitations, and
as a proof of principle, we focused on homologous
recombination-based gene correction of multiple
mutations on lamin A (LMNA), which are associated
with various degenerative diseases. We show that
helper-dependent adenoviral vectors (HDAdVs)
provide a highly efficient and safemethod for correct-
ing mutations in large genomic regions in human
induced pluripotent stem cells and can also be effec-
tive in adult humanmesenchymal stemcells. This type
of approach could be used to generate genotype-
matched cell lines for disease modeling and drug
discovery and potentially also in therapeutics.
INTRODUCTION
The development of targeted gene-editing technologies in
human induced pluripotent stem cells (hiPSCs) and human
embryonic stem cells (hESCs) may not only open the opportunity
for a` la carte cell engineering but also offer the potential for the
efficient treatment and/or cure of multiple human diseases.
Recently, several technologies have been developed allowing
for gene targeting in human embryonic stem cells (hESCs) and
hiPSCs (Buecker et al., 2010; Ha¨ndel and Cathomen, 2011;
Hockemeyer et al., 2009; Howden et al., 2011; Irion et al.,
2007; Khan et al., 2010; Lombardo et al., 2007; Mitsui et al.,
2009; Nieminen et al., 2010; Sancho-Martinez et al., 2011;
Song et al., 2010; Suzuki et al., 2008; Tenzen et al., 2010; Zou
et al., 2009; Zwaka and Thomson, 2003). However, despite
numerous efforts and recent advancements, major problems688 Cell Stem Cell 8, 688–694, June 3, 2011 ª2011 Elsevier Inc.remain unresolved. First, the classical nonviral vectors and
delivery approaches are associated with low efficiency of gene
targeting in human pluripotent stem cells, especially for tran-
scriptionally silenced genomic loci (Goulburn et al., 2011; Ruby
and Zheng, 2009; Wang et al., 2011; Xue et al., 2009). Second,
the current technologies introduce DNA double-strand breaks
(DSBs) (Arnould et al., 2011; Ha¨ndel and Cathomen, 2011; Miller
et al., 2011). Accordingly, the potential for off-target effects
leading to unexpected mutations and chromosomal aberrations
might not be acceptable for therapeutic applications. Moreover,
for genes bearing mutational ‘‘hot spots’’ (Worman et al., 2010),
efficient tools targeting multiple sites spanning a large DNA
sequence still need to be developed.
In the present workwe sought to address some of these issues
by taking advantage of a recently established LMNA-based iPSC
model of disease (Liu et al., 2011). LMNA is a known transcrip-
tionally inactive locus in pluripotent cells. Importantly, more
than 400 different mutations of LMNA have been reported, with
additional mutations continuously being discovered (Zaremba-
Czogalla et al., 2011). Thus, LMNA represents an ideal candidate
locus for the study of hot-spot gene correction of silenced genes
by using single vectors targeting large genomic regions. LMNA
encodes lamin A, an architectural component of nuclear lamina
in somatic cells indispensable for nuclear integrity (Dechat
et al., 2008). Mutations on lamin A are associated with disruption
of the nuclear structure, aberrant cellular function, and disease
development, defining a group of human degenerative diseases
referred to as laminopathies (Burke et al., 2001; Worman et al.,
2010; Zaremba-Czogalla et al., 2011). One of the best-known
laminopathies is Hutchinson-Gilford progeria syndrome (HGPS
or progeria), a premature aging disorder associated with the
presence of a specific mutation of the LMNA gene. Such muta-
tion results in a truncated mRNA encoding the mutant protein
progerin (Burtner andKennedy, 2010). Progerin plays a dominant
role in the nucleus and its accumulation can result in a number of
different nuclear defects, accelerated aging, and cellular senes-
cence (Dechat et al., 2008; Scaffidi and Misteli, 2005).
Recently we and others have reported the generation of iPSCs
(HGPS-iPSCs) from HGPS patient fibroblasts (Liu et al., 2011;
Zhang et al., 2011). Here we report the establishment of an effi-
cient and highly specific method for correction of a number of
LMNA mutations. Indeed, the use of a single helper-dependent
adenoviral vector (HDAdV) was sufficient for the correction of
Figure 1. Correction of HGPS-Associated LMNA Mutation in iPSCs with LMNA-c-HDAdV
(A) Schematic molecular representation of LMNA gene correction with LMNA-c-HDAdV. The primers for PCR are shown as arrows (P1, P2, P3, and P4). The
probes for Southern analyses are shown as black bars (50 probe and 30 probe). HSVtk stands for herpes simplex virus thymidine kinase gene cassette used for
negative selection; neo stands for neomycin-resistant gene cassette used for positive selection; CMV-b-gal indicates the b-gal expression cassette for deter-
mination of HDAdV titer; blue triangle, FRT site; red X, mutation sites in exon 11.
(B) Schematic representation of the gene-correction approach employed in iPSCs with laminopathy-associated mutation(s).
(C) Gene-targeting and gene-correction efficiencies at the LMNA locus in HGPS-iPSCs achieved by different infection conditions. N.D., not determined.
(D) PCR analyses of HGPS-iPSCs and cHGPS-iPSCs via 50 primer pair (P1 and P2; 13.9 kb) or 30 primer pair (P3 and P4; 9.4 kb). M, DNA ladder.
(E) Southern blot analyses of HGPS-iPSCs and cHGPS-iPSCs. The approximate molecular weights (kb) corresponding to the bands are indicated.
(F) Sequencing results of C1824T mutation site in exon 11 of LMNA in BJ-iPSCs (wild-type), HGPS-iPSCs, and cHGPS-iPSCs. All iPSCs employed represent
high-passage iPSCs (>30).
See also Figure S1.
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LMNA gene. Targeted correction of LMNA led to the restored
expression of wild-type lamin A and to the abolishment of
progerin expression. Consequently, lack of progerin expression
resulted in the correction of the disease-associated cellular
phenotypes, including decelerated senescence and restoration
of normal nuclear morphology. Furthermore, the use of
HDAdV-based approaches demonstrated very high efficiencies
in the absence of any observed genetic and epigenetic abnor-
mality and led to indistinguishable cell genetic backgrounds
before and after gene targeting. Thus, the method described
here might represent a more efficient and safer alternative to
other current technologies. Along the same line, HDAdV-based
approaches can be used for the generation of genetically
matched iPSCs serving as a more reliable control for disease
modeling and drug discovery. Lastly, ourmethodologies demon-
strate the use of HDAdV-based gene targeting as a reliable tool
for the engineering of adult mesenchymal stem cells (MSCs).
RESULTS AND DISCUSSION
HDAdV-Based Gene Correction Shows High Efficiency
in Transcriptionally Inactive Locus
Of the 12 exons of the LMNA gene, exons 2 to 12 cluster closely
together. This region covers around 80% of the whole LMNA
coding sequence and accumulates up to 246 of the published
mutations in the LMNA gene (http://www.umd.be/LMNA/).
With the aim to develop a single method amenable for thecorrection of multiple LMNA mutations, we engineered
a HDAd-based gene-correction vector (LMNA-c-HDAdV) (Fig-
ure 1A). HDAdV has been proven tomediate efficient and precise
gene editing in hESCs without the requirement for artificial DNA
DSBs (Suzuki et al., 2008). Because of the complete removal of
viral genes from the vector, HDAdVs show low cytotoxicity while
displaying the major advantage of having a large cloning
capacity (37 kb). Thus, HDAdVs permit the insertion of long
homologous DNA regions that are designed to facilitate
targeted integration via homologous recombination (HR) (Suzuki
et al., 2008).
In view of these advantages, we first evaluated the ability of
LMNA-c-HDAdV to correct the HGPS-associated LMNA muta-
tion C1824T in exon 11 in HGPS-iPSCs. We initially tested
various viral infection conditions as well as different multiplicities
of infection (MOIs). The system here employed includes a nega-
tive selection step by ganciclovir (GANC) resistance. If the vector
randomly integrates into the genome, the integrated DNAwill still
include an HSVtk cassette leading to cell death by GANC selec-
tion. On the other hand, if the vector integrates at the targeted
site by HR, the HSVtk cassette is removed and the cell displays
GANC resistance (Mansour et al., 1988). Thus, negative selection
helps to minimize ectopic vector integration (Suzuki et al., 2008).
Accordingly, after sequential positive (G418) and negative
(GANC) selection (Mansour et al., 1988), double-resistant
colonies were expanded and maintained in hESC medium
(Figure 1B). Effective gene targeting at the LMNA loci in drug-
resistant clones was verified by PCR and Southern blot (FiguresCell Stem Cell 8, 688–694, June 3, 2011 ª2011 Elsevier Inc. 689
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because of the transcriptional inactivation of the LMNA locus
in HGPS-iPSCs (Liu et al., 2011; Zhang et al., 2011), gene-target-
ing efficiencies would be considerably low as previously
described for other methodologies (Goulburn et al., 2011; Ruby
and Zheng, 2009; Wang et al., 2011; Xue et al., 2009). Surpris-
ingly, efficient gene targeting of LMNA (78%–100%) was consis-
tently obtained evenwith the lowest MOI used (Figure 1C). These
results indicate that high-targeting efficiency might saturate the
system, allowing for reduced number of viral particles. We
arbitrarily selected the iPSC colonies that were infected as single
cells with the lowest viral titer (MOI = 3) for further analysis. Since
most laminopathy-associated mutations are heterozygous, we
expected gene-correction efficiencies to be 50% of the total
frequency of gene-targeting events. Accordingly, DNA se-
quencing showed that mutations in 46% of the drug-resistant
colonies were successfully corrected (Figures 1C and 1F).
Gene Correction by LMNA-c-HDAdV Maintains
Genetic and Epigenetic Integrity and Reverses
Disease-Associated Phenotypes
In order to achieve genomic integrity in the corrected clones, we
next excised the neomycin-resistant gene cassette, flanked by
FRT sites, by transient expression of FLPe recombinase (Fig-
ure S1B). The neo-removed corrected HGPS-iPSC lines (here-
after referred to ‘‘cHGPS-iPSCs’’) showed a normal karyotype,
expressed pluripotent markers, and exhibited demethylation of
the OCT4 promoter and pluripotency (Figures S1C–S1I; Movie
S1). Genome-wide single nucleotide polymorphism (SNP) geno-
typing demonstrated that the genetic background of the cHGPS-
iPSCs was the same as the parental HGPS fibroblasts, but
distinct from H9 hESCs and the control BJ-iPSCs (Figure 2A;
Table S1). By copy number variation (CNV) of the SNP genotyp-
ing data, using the method described in Laurent et al. (2011),
there were no detected new duplications or deletions in the
cHGPS-iPSCs compared to the HGPS-fibroblast cells (Fig-
ure 2B). Although this result may appear to be at variance with
a recent report by Hussein et al. (2011), there were significant
differences between the samples analyzed. Hussein et al.
(2011) reported a higher frequency of CNVs in very early passage
(<10 passages) when compared to later-passage iPSCs and
postulated that these CNVs occurred during the process of
reprogramming and were negatively selected in culture. Thus,
because our gene targeting experiments started with HGPS-
iPSCs at passage 30, our corrected iPSCs (>passage 30) clearly
surpassed that early window of high-frequency CNV. Both SNP
arrays used in the two studies assayed1 million SNPs, and the
analyses required consistent calls for a minimum of ten adjacent
markers to identify a CNV; therefore the controversies observed
betweenHussein’s and our own results were not due to technical
but to passage number differences. DNA microarray analysis
revealed very similar expression profiles between cHGPS-iPSCs
and their parental HGPS-iPSCs (Figure 2C), indicating that the
targeting procedure did not alter global gene expression. To
examine whether the gene-targeting procedure interfered with
the global epigenetic state, we performed genome-wide DNA
methylation analysis. An average of 12 million single-end 80 bp
sequencing reads was generated for each sample, yielding an
average read depth of >503 for all CpG sites called, which is690 Cell Stem Cell 8, 688–694, June 3, 2011 ª2011 Elsevier Inc.roughly twice as high as the published whole-genome bisulfite
sequencing data (Lister et al., 2011). The methylation levels
measured on theWatson strand and the Crick strandwere highly
consistent for the same CpG sites (Pearson correlation coeffi-
cient r = 0.965 for site with read depth R 10), indicating that
the methylation measurements were very accurate. As shown
in Figure 2D, the cHGPS-iPSCs showed a highly similar methyl-
ation profile as its parental iPSCs, in contrast to hESCs and wild-
type iPSCs. Thus, our gene correction approach effectively
maintained genetic and epigenetic cell integrity.
To ascertain whether correction of themutant LMNA in HGPS-
iPSCs is able to prevent development of some of the disease-
associated phenotypes, we differentiated the cHGPS-iPSCs
into vascular smooth muscle cells (SMCs) and fibroblasts, two
known HGPS-affected cell types (Liu et al., 2011; Zhang et al.,
2011). Immunoblotting and RT-PCR analysis did not detect
progerinmRNAor protein in cHGPS-iPSCs-derived cells (Figures
2E–2G). These results correlated with a significant rescue of the
senescence phenotype. Senescence-associated (SA)-b-gal
staining was reduced from 21.3% in SMCs differentiated from
thenoncorrectedHGPS-iPSCs to6.8% incHGPS-iPSCs-derived
SMCs, compared to 11.4% observed in BJ-iPSC-derived SMCs
(Figure 2H). In addition, cHGPS-iPSCs-derived fibroblasts
showed more than 60% reduction in the number of abnormal
nuclei as compared to noncorrected counterparts (Figure 2I).
Altogether, our results show that genetic correction of HGPS-
iPSCs completely abrogated expression of progerin and resulted
in expression of wild-type lamin A, thus leading to restored
nuclear architecture and a normal cell senescence program.
LMNA-c-HDAdV Spans Large Genomic Regions and
Could Be Used for the Correction of Multiple Mutations
Considering the large DNA-carrying capacity of our generated
LMNA-c-HDAdV, we next decided to examine whether the
same approach could be used to correct other LMNAmutations.
We generated iPSCs from a patient with atypical Werner
syndrome (AWS), a milder premature aging disease caused by
a different LMNA mutation (A1733T in exon 11, E578V) (Csoka
et al., 2004). AWS-iPSCs demonstrated acquisition of the typical
iPSC characteristics including expression of pluripotency
markers, ability to differentiate in vitro, formation of teratomas,
and pluripotent gene expression and DNA methylation signa-
tures (Figures 2C, 2D, 3A, and 3B; Figure S1G). In addition,
AWS-iPSCs showed a normal karyotype and carried the
disease-specific LMNA mutation (Figure 3F; Figure S1C). By
employing the same approach used for the correction of
HGPS-iPSCs, we obtained gene-targeting efficiencies ranging
from 89% to 100% and specific gene correction of up to 35%
(Figures 3C–3F; Figure S1J). The corrected AWS-iPSCs
(cAWS-iPSCs) expressed pluripotent markers and showed
a normal karyotype as well as a highly similar DNA methylation
and gene expression profile as their parental AWS-iPSCs
(Figures 2C and 2D; Figure S1C and S1E). These observations
highlight the possibility of using a single LMNA-c-HDAdV vector
for the correction of multiple mutations of the LMNA gene and
thus for the treatment of different laminopathies.
We next sought to determine the maximal region that LMNA-
c-HDAdV covers. To this end, we sequenced the whole LMNA
locus in HGPS- and AWS-iPSCs looking for specific SNP sites
Figure 2. Abrogation of HGPS-Associated Phenotypes by Correction of LMNA in iPSCs
(A) Replicate error analysis indicating that cHGPS-iPSCs and HGPS fibroblasts were essentially genetically identical, whereas HGPS fibroblasts, H9 hESCs, and
BJ-iPSCs came from unrelated individuals.
(B) CNV calling via CNVPartition, identifying one region of duplication (CNV value = 3) at chr7:141322-162448, which was present in both the original HGPS
fibroblasts and cHGPS-iPSCs.
(C) Hierarchical clustering on RMA-normalized probe sets intensity values for HGPS- and AWS-iPSCs before and after gene correction, and their original
fibroblast cell lines.
(D) Hierarchical clustering on genome-wide DNA methylation profiles of the indicated cell lines.
(E) Immunoblotting analysis of lamin A/C and progerin expression in the indicated cell lines with lamin A/C antibody. Tubulin was used as loading control. d-SMC,
iPSC-derived SMC; d-fib, iPSC-derived fibroblast.
(F) RT-PCR analysis of expression of full-length lamin A (top band) and truncated lamin A (progerin; bottom band) in hESC/iPSC-derived SMCs (passage 3) with
the indicated primer pair. GAPDH was used as loading control.
(G) Quantitative RT-PCR analysis of progerin expression in BJ-iPSC-, HGPS-iPSC-, or cHGPS-iPSC-derived SMCs at passage 3. **p < 0.01.
(H) Senescence-associated (SA)-b-gal staining of SMCs derived from HGPS-iPSC or cHGPS-iPSC at passage 5. Correction of HGPS-iPSCs resulted in more
than a 68% reduction on the derived SMCs undergoing senescence; *p < 0.05, **p < 0.01.
(I) Immunostaining of lamin A in iPSC-derived fibroblasts at passage 15. Arrows denote dysmorphic nuclei. Dysmorphic nuclei were quantified and represented
in the lower panels. **p < 0.01. Data are shown as mean ± SD; n = 3. Scale bar represents 20 mm. All iPSCs employed represent high-passage iPSCs (>30).
See also Figure S1, Table S1, and Movie S1.
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AWS-specific SNP sites located downstream of exon 12 were
found on the same chromosome as the AWS mutation in the
noncorrected cells and were used as a read-out for our analysis
(Figure 3G). These two SNP sites are located 3.3 and 4.4 kb
downstreamof the neo-insertion site, respectively. By examining
the presence of these two SNPs in the corrected AWS-iPSCs, we
found that both of them were effectively replaced by the wild-
type LMNA-c-HDAdV sequence (60% of the gene-corrected
clones) (Figure 3H), indicating that the majority of HR events
occur outside of the second SNP site. Since exons 3–12 arealso located within the 4.4 kb region from neo-insertion site (Fig-
ure 3I), our results suggest that LMNA-c-HDAdV can at least
replace the whole exon 3–12 region. Thus, our method could
potentially be used to correct more than 200 different mutations
described in the LMNA locus.
Targeting of LMNA Locus with LMNA-c-HDAdV
Can Be Achieved in Adult Stem Cells
Finally, we evaluated the possibility of using HDAd-based
vectors for gene editing in human adult stem cells. We focused
on mesenchymal stem cells (MSCs) because of their currentCell Stem Cell 8, 688–694, June 3, 2011 ª2011 Elsevier Inc. 691
Figure 3. Editing the LMNA Locus in iPSCs and MSCs via LMNA-c-HDAdV
(A) Immunostaining of different pluripotency markers in AWS-iPSCs. Nuclei were stained with Hoechst 33342. Scale bars represent 20 mm.
(B) H&E staining (left) and immunofluorescence (right) of three germ layer-specific markers (endoderm: AFP, FOXA2; mesoderm: ASMA, ASA; ectoderm: Tuj1,
GFAP) in teratomas derived from AWS-iPSCs. Nuclei were stained with DAPI.
(C) Gene-targeting and gene-correction efficiencies at the LMNA locus in AWS-iPSCs achieved by different infection conditions. N.D., not determined.
(D) PCR analyses of AWS-iPSCs and gene-corrected AWS-iPSCs (cAWS-iPSCs) via 50 primer pair (P1 and P2; 13.9 kb) or 30 primer pair (P3 and P4; 9.4 kb). M,
DNA ladder.
(E) Southern blot analyses of AWS-iPSCs and cAWS-iPSCs. The approximate molecular weights (kb) corresponding to the bands are indicated.
(F) Sequencing results of A1733T mutation site in exon 11 in BJ-iPSCs (wild-type), AWS-iPSCs, and cAWS-iPSCs.
(G) Schematic molecular representation of mutation- and SNP-correction with LMNA-c-HDAdV in AWS-iPSCs. Themutation site (A1733T) and SNP sites 1 and 2
are located 0.3, 3.3, and 4.4 kb downstream of the neo-insertion site, respectively, on the same chromosome as the AWS mutation.
(H) Sequencing results of SNP sites 1 and 2 downstream of exon 12 in cAWS-iPSCs with and without SNP correction.
(I) Schematic illustration of the putative gene editing capacity of LMNA-c-HDAdV at LMNA locus.
(J) Gene-targeting efficiency in OE-MSCs with LMNA-c-HDAdV achieved by different infection conditions. All iPSCs employed represent high-passage
iPSCs (>30).
See also Figure S1.
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mann, 2010). LMNA mutations mainly affect mesoderm-derived
tissues, such as muscle and adipocytes. Thus, LMNA correction
onMSCs could represent an attractive alternative for therapeutic
purposes (Zaremba-Czogalla et al., 2011). Because of their high
cell-cycle kinetics which enables effective clonal expansion, we
specifically focused on olfactory ectomesenchymal stem cells
(OE-MSCs) (Delorme et al., 2010). Furthermore, OE-MSCs are
easily accessible by noninvasive biopsies and therefore repre-
sent an attractive cell population for clinical applications (De-
lorme et al., 2010). As shown in Figure 3J and Figures S1K and
S1L, LMNA-c-HDAdV demonstrated gene-editing efficiency of
54% in wild-type OE-MSCs, without disruption of the normal
lamin A/C expression. Although OE-MSCs from patients with692 Cell Stem Cell 8, 688–694, June 3, 2011 ª2011 Elsevier Inc.laminopathies are not available at this stage, our study suggests
in particular the possibility that LMNA-c-HDAdV could be used
to genetically modify laminopathy-specific MSCs in the future,
and more generally, the feasibility of targeting adult stem cells
for gene correction.
In summary, we report the successful correction of different
laminopathy-associated LMNA mutations in patient-specific
iPSCs with a single gene correction vector. Moreover, HDAdV-
based approaches efficiently target specific genomic loci on
adult stem cells, a scenario not previously addressed. Our
results demonstrate that the long homology arms used in
HDAdVs have the capability to edit the targeted genomic locus
without off-target effects and/or introduction of additional muta-
tions, thus presenting an advantageous alternative to the use of
Cell Stem Cell
High Efficient Gene Targeting on hiPSCs and MSCsother gene-editing technologies (Hockemeyer et al., 2009).
Although bacterial artificial chromosome (BAC)-mediated
vectors also used long homology arms, their ability and
efficiency to target the genomewas restricted to transcriptionally
active loci (Howden et al., 2011; Song et al., 2010). Here we show
that LMNA-c-HDAdV can specifically edit transcriptionally
inactive loci with high efficiencies. Thus, the HDAdV represents
a robust and versatile tool that could be applied toward the
correction of multiple monogenic diseases. Finally, this ap-
proach could serve to generate appropriate genotype-matched
iPSC lines in disease modeling and drug discovery studies.
EXPERIMENTAL PROCEDURES
Construction and Preparation of LMNA-c-HDAdV
LMNA-c-HDAdV was generated with a BAC clone, containing the human
LMNA loci (RP11-54H19, BACPAC resources), that were modified with BAC
recombineering (Datsenko and Wanner, 2000). In brief, the FRT-PGK-EM7-
neo-bpA-FRT fragment was recombined into intron 10 of LMNA in the BAC
clone. A total of 23.2 kb of LMNA homology, including the marker cassette,
was subcloned into the HDAdV plasmid pAMHDAdGT8-4 (kindly provided by
Dr. Kohnosuke Mitani). The generated LMNA-c-HDAdV was linearized by
PmeI and then transfected into 116 cells (kindly provided by Dr. Philip Ng)
in the presence of helper virus AdHPBGF35 (kindly provided by Dr. Andre´ M.
Lieber) (Shayakhmetov et al., 2004). Crude virus extractswere serially amplified
in 116 cells and then purified according to the method previously described
(Palmer and Ng, 2004). b-gal-transducing units (btu) were determined in 293
cells to define infectious vector titers.
Immunofluorescence Analysis
4% formaldehyde in PBS was used to fix cells at room temperature (RT) for
20–30 min. After fixation, cells were exposed to 0.4% Triton X-100 in PBS
for 5 min at RT. Cells were blocked with 10% FBS in PBS for 30 min and incu-
bated with primary antibody for 1 hr at RT or overnight at 4C. Washing was
conducted with PBS followed by incubation with a corresponding secondary
antibody for 1 hr at RT. Hoechst 33342 or DAPI was used to stain nuclei.
Teratoma Analysis
To test pluripotency in vivo, iPSC lines were injected into NOD-SCID IL2Rgam-
manull mice (Jackson Laboratories) and teratoma formation was assessed. In
short, 106 iPSCs in 50 ml of hESC medium were injected into the kidney
capsule or testis of anesthetized mice. Teratoma formation was monitored
and animals were sacrificed6–12weeks after injection. Harvested teratomas
were processed and analyzed by immunostaining and hematoxylin-eosin
staining. All murine experiments were conducted with approval of The Salk
Institute Institutional Animal Care and Use Committee (IACUC).
Statistical Analysis
Results are presented as mean ± SD. Student’s t test was applied to all
comparisons. Statistical significance was defined as p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
one figure, one table, and one movie and can be found with this article online
at doi:10.1016/j.stem.2011.04.019.
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